MCID: EXT010
MIFTS: 45

Extramedullary Plasmacytoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Extramedullary Plasmacytoma

MalaCards integrated aliases for Extramedullary Plasmacytoma:

Name: Extramedullary Plasmacytoma 12 15 70 32
Plasmacytoma, Extramedullary 12
Extraosseous Plasmacytoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3720
NCIt 50 C4002
SNOMED-CT 67 128921005
ICD10 32 C90.2
UMLS 70 C0278619

Summaries for Extramedullary Plasmacytoma

MalaCards based summary : Extramedullary Plasmacytoma, also known as plasmacytoma, extramedullary, is related to plasma cell neoplasm and plasmacytoma. An important gene associated with Extramedullary Plasmacytoma is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Ketamine and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone marrow and colon, and related phenotypes are cellular and hematopoietic system

Related Diseases for Extramedullary Plasmacytoma

Diseases related to Extramedullary Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 plasma cell neoplasm 30.7 SDC1 MYOM2 IL6 B2M
2 plasmacytoma 30.5 IRF4 IL6 IL2 IGKC CD79A CD38
3 amyloid tumor 30.4 MYOM2 B2M
4 amyloidosis 30.3 MYOM2 IL6 IGKC CCND1 B2M
5 post-transplant lymphoproliferative disease 30.3 IL6 B2M
6 poems syndrome 30.2 MYOM2 IL6 IL2
7 indolent plasma cell myeloma 30.1 MYOM2 IL6
8 b-cell lymphoma 30.1 IRF4 CDKN1A CCND1 BCL2L1 BCL2
9 lymphoma, hodgkin, classic 30.1 IRF4 IL2 BCL2L1 BCL2
10 epiglottis neoplasm 29.9 CD79A CCND1
11 pancreatic adenocarcinoma 29.9 IL6 CDKN1A CCND1 BCL2L1
12 gamma heavy chain disease 29.9 SDC1 CD38
13 acute promyelocytic leukemia 29.8 IL6 CDKN1A CCND1 BCL2L1 BCL2
14 heavy chain disease 29.7 MYOM2 CD79A
15 solitary osseous plasmacytoma 29.6 SDC1 MYOM2 CD79A CD38 B2M
16 burkitt lymphoma 29.6 IRF4 IL6 CDKN1A BCL2L1 BCL2
17 myeloma, multiple 29.5 SDC1 MYOM2 IRF4 IL6 IL2 CD38
18 renal cell carcinoma, nonpapillary 29.4 IL2RB IL2 CCND1 BCL2L1 B2M
19 plasma cell leukemia 29.4 SDC1 IRF4 IL6 CD38 CCND1
20 peripheral nervous system disease 29.3 MYOM2 IL6 IL2 CCND1 BCL2L1 B2M
21 marginal zone b-cell lymphoma 29.1 SDC1 IRF4 CD79A CCND1 BCL2
22 lymphoma 29.1 IRF4 IL6 IL2 CD38 CCND1 BCL2L1
23 acquired immunodeficiency syndrome 28.9 IL6 IL2RB IL2 CD79A CD38 B2M
24 immune deficiency disease 28.9 IL6 IL2RB IL2 CD79A CD38 B2M
25 lymphoma, mucosa-associated lymphoid type 28.8 SDC1 IRF4 IGKC CD79A CCND1 BCL2
26 monoclonal gammopathy of uncertain significance 28.5 SDC1 MYOM2 IRF4 IL6 CD38 CCND1
27 leukemia, acute myeloid 28.4 IL6 IL2 CDKN1A CD79A CD38 CCND1
28 diffuse large b-cell lymphoma 28.1 SDC1 IRF4 IL6 CD79A CD38 CCND1
29 lymphoma, non-hodgkin, familial 27.6 SDC1 IRF4 IL6 IL2RB IL2 CD79A
30 leukemia, chronic lymphocytic 27.5 SDC1 IRF4 IL6 IL2 CD79A CD38
31 rare tumor 10.6
32 thyrotoxic exophthalmos 10.4 IL6 CCND1
33 plasma cell tumor 10.3
34 clear cell adenocarcinoma of the ovary 10.3 IFI27 CCND1
35 obstructive jaundice 10.3
36 absolute glaucoma 10.3 BCL2L1 BCL2
37 thyroiditis 10.3
38 exophthalmos 10.3
39 dysphagia 10.3
40 suppressor of tumorigenicity 3 10.3 CDKN1A BCL2
41 uremic pruritus 10.3 IL6 IL2
42 human herpesvirus 8 10.2 IL6 BCL2
43 pyuria 10.2 IL6 B2M
44 intestinal obstruction 10.2
45 chondromyxoid fibroma 10.2 CDKN1A CCND1 BCL2
46 superficial basal cell carcinoma 10.2 IL6 IL2
47 extramedullary soft tissue plasmacytoma 10.2
48 virus associated hemophagocytic syndrome 10.2 IL2RB IL2
49 t-cell non-hodgkin lymphoma 10.2 IGKC B2M
50 osteosclerotic myeloma 10.2 MYOM2 IL6

Graphical network of the top 20 diseases related to Extramedullary Plasmacytoma:



Diseases related to Extramedullary Plasmacytoma

Symptoms & Phenotypes for Extramedullary Plasmacytoma

MGI Mouse Phenotypes related to Extramedullary Plasmacytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 B2M BCL2 BCL2L1 CCND1 CD38 CD79A
2 hematopoietic system MP:0005397 10.15 B2M BCL2 BCL2L1 CCND1 CD38 CD79A
3 endocrine/exocrine gland MP:0005379 10.1 B2M BCL2 BCL2L1 CCND1 CD38 CDKN1A
4 homeostasis/metabolism MP:0005376 10.06 B2M BCL2 BCL2L1 CCND1 CD38 CD79A
5 immune system MP:0005387 10.03 B2M BCL2 BCL2L1 CCND1 CD38 CD79A
6 integument MP:0010771 9.81 B2M BCL2 BCL2L1 CCND1 CDKN1A IL2RB
7 neoplasm MP:0002006 9.65 B2M BCL2 BCL2L1 CCND1 CD79A CDKN1A
8 reproductive system MP:0005389 9.28 B2M BCL2 BCL2L1 CCND1 CDKN1A IL2

Drugs & Therapeutics for Extramedullary Plasmacytoma

Drugs for Extramedullary Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
3
Morphine Approved, Investigational Phase 3 57-27-2 5288826
4
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 3 14838-15-4 26934
5
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
6
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
7
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
8
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
9
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
10
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Dalteparin Approved Phase 3 9005-49-6
13
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
14
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
15
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
16 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
17 Anesthetics, Dissociative Phase 3
18 Proteasome Inhibitors Phase 3
19 Antiparasitic Agents Phase 3
20 Antiprotozoal Agents Phase 3
21 Respiratory System Agents Phase 3
22 Narcotics Phase 3
23 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
24 Analgesics, Opioid Phase 3
25 Antitussive Agents Phase 3
26 Analgesics Phase 3
27 Neurotransmitter Agents Phase 3
28 Excitatory Amino Acid Antagonists Phase 3
29 Hematinics Phase 3
30 ferric gluconate Phase 3
31 Iron Supplement Phase 3
32 Cola Phase 3
33 Liver Extracts Phase 3
34 Anticoagulants Phase 3
35 Epoetin alfa Phase 3 113427-24-0
36 Dermatologic Agents Phase 3
37 Antifungal Agents Phase 3
38 Liposomal amphotericin B Phase 3
39 Amebicides Phase 3
40 Psychotropic Drugs Phase 3
41 Anti-Anxiety Agents Phase 3
42 Antipsychotic Agents Phase 3
43 Fibrinolytic Agents Phase 3
44 Heparin, Low-Molecular-Weight Phase 3
45
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
47
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
48
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
49
Acyclovir Approved Phase 2 59277-89-3 2022
50
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Study of Cyclophosphamide,Liposome Doxorubicin Dexamethasone(CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
3 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
4 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
5 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
6 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
7 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
9 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
10 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
12 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
14 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
15 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
16 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
17 Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and Promace-Cytabom For Treatment of Post-Cardiac Transplant Lymphoproliferation. Completed NCT00002657 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;methotrexate;prednisone;vincristine sulfate
18 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
19 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
20 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
21 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
22 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
23 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
24 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
25 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
26 Adoptive Immunotherapy of Epstein Barr Virus Induced Lymhoproliferative Disease. A Comparison of Allogeneic and Autologous Lymphocyte Responses ex Vivo and Use of Highly Selected Reactive Cells as an Alternative to Chemotherapy in Vivo. Completed NCT00005606 Phase 2
27 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
28 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
29 Short Course Daratumumab in Minimal Residual Disease (MRD) Positive Myeloma Patients After Induction Therapy With/Without Consolidative High Dose Chemotherapy/Autologous Stem Cell Support Recruiting NCT03490344 Phase 2 Daratumumab;Lenalidomide
30 A Prospective Observational Study of Patients With Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan Terminated NCT00109889 Phase 2
31 Single Autologous Transplant Followed by Consolidation and Maintenance for Participants ≥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy Terminated NCT01849783 Phase 2 dexamethasone;cisplatin;doxorubicin;cyclophosphamide;etoposide;bortezomib;thalidomide;melphalan
32 Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI) Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
33 Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
34 An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
35 Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies Completed NCT00004232 Phase 1 cyclosporine;methylprednisolone;prednisone
36 A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies Completed NCT00002980 Phase 1 decitabine
37 A Phase I Clinical And Pharmacological Study Of Pyroxamide (NSC 696085) In Patients With Advanced Malignancies Completed NCT00042900 Phase 1 pyroxamide
38 A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies Completed NCT00003331 Phase 1 fluorouracil;leucovorin calcium;topotecan hydrochloride
39 A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients Completed NCT00003082 Phase 1
40 Phase I Trial of Interleukin-12 Followed by Interferon-Alpha Completed NCT00003451 Phase 1
41 A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Patients With Advanced Solid Tumors and B-cell Lymphoproliferative Disorders Completed NCT00006362 Phase 1 bortezomib
42 Phase I Clinical and Pharmacological Study of Suberoylanilide Hydroxamic Acid- SAHA (MSK390) in Patients With Advanced Solid Tumors Completed NCT00005634 Phase 1 vorinostat
43 Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 "Veto" Cells Completed NCT00004904 Phase 1 cladribine;cyclophosphamide;etoposide;methylprednisolone;tacrolimus
44 A Phase I Trial of EMD 121974 in Patients With Advanced or Metastatic Cancer Completed NCT00004258 Phase 1 cilengitide
45 Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders Terminated NCT00004058 Phase 1 tetradecanoylphorbol acetate
46 Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia Completed NCT00993694 chemotherapy;dapsone
47 Fungemia Survey in Cancer Patients Completed NCT00445952
48 Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy Completed NCT00376922
49 Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET) Recruiting NCT00935090
50 Carolina Senior: UNC Registry for Older Cancer Patients Active, not recruiting NCT01137825

Search NIH Clinical Center for Extramedullary Plasmacytoma

Genetic Tests for Extramedullary Plasmacytoma

Anatomical Context for Extramedullary Plasmacytoma

MalaCards organs/tissues related to Extramedullary Plasmacytoma:

40
Thyroid, Bone Marrow, Colon, Pancreas, Bone, Lymph Node, Skin

Publications for Extramedullary Plasmacytoma

Articles related to Extramedullary Plasmacytoma:

(show top 50) (show all 1152)
# Title Authors PMID Year
1
Extramedullary plasmacytoma involving rectum: A case report and literature review. 61
33537109 2021
2
Obstructive rectosigmoid colon solitary extramedullary plasmacytoma. 61
33376074 2021
3
Amyloidosis, extramedullary plasmacytoma, and light chain deposition disease: impressive results of daratumumab therapy. 61
33567803 2021
4
Utilization of radiation therapy in multiple myeloma: trends and changes in practice. 61
33438047 2021
5
A rare case of primary solitary endobronchial plasmacytoma. 61
33501775 2021
6
Solitary Plasmacytoma of the Frontal Bone. 61
33108859 2021
7
Unusual presentation of a soft palate mass: A rare case report of solitary extramedullary plasmacytoma. 61
33482447 2021
8
Myeloma of Laryngeal Cartilage: Literature Review and Case Study. 61
31284752 2021
9
Detection of Nasal Solitary Extramedullary Plasmacytoma on 18F-FDG PET/CT Imaging. 61
33630797 2021
10
Extramedullary plasmacytoma of the pancreas diagnosed by EUS-guided fine-needle biopsy (with videos). 61
33473045 2021
11
A rare cause of diplopia: Solitary extramedullary plasmacytoma of the skull base. 61
32985218 2021
12
18F-FDG PET/CT in the Evaluation of Solitary Extramedullary Plasmacytoma: A Case Series. 61
33392351 2021
13
Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial-ethnic group, United States 2003-2016. 61
33270992 2021
14
Intraocular solitary extramedullary plasmacytoma presenting as unilateral anterior and intermediate uveitis preceded by refractory glaucoma. 61
33516180 2021
15
Cauda Equina Syndrome as the Initial Presentation of Concurrent Plasmacytoma and Multiple Myeloma. 61
33643734 2021
16
A Giant Solitary Adrenal Plasmacytoma in a Patient with HIV: A Rare Case Report and Review of the Literature. 61
33614176 2021
17
Extramedullary Plasmacytoma of the breast in a patient with Multiple Myeloma. 61
33717400 2020
18
Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma. 61
33082903 2020
19
Tracheal extramedullary plasmacytoma: a rare cause of chronic cough. 61
33305556 2020
20
Extramedullary Plasmacytoma of False Vocal Cord: Case Report. 61
33155846 2020
21
Surgery results in low relapse and progression rates in extramedullary plasmacytoma of the head and neck: A case cohort and review of the literature. 61
33282164 2020
22
Corrigendum to "Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings" [Radiology Case Reports 14 (2019) 584-587]. 61
33088369 2020
23
Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry. 61
32783165 2020
24
Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. 61
33201300 2020
25
Long-term Follow-up After Radiation Therapy for Laryngeal Amyloidosis. 61
33009850 2020
26
Long-term Outcomes After Definitive Radiation Therapy for Solitary Plasmacytoma. 61
32739971 2020
27
Primary pulmonary plasmacytoma accompanied by overlap syndrome: A case report and review of the literature. 61
33195673 2020
28
Evaluation of Extramedullary Plasmacytoma of the Larynx with Radiologic and Histopathological Findings. 61
33268135 2020
29
Response dataset from canine extramedullary plasmacytoma treated with lipophobic drugs enhanced by electroporation. 61
32802920 2020
30
Anaplastic extraosseous (extramedullary) plasmacytoma in the right nostril. 61
33012497 2020
31
Extramedullary Plasmacytoma of Nasal Cavity: A Case Report and Literature Review. 61
33044842 2020
32
Extramedullary plasmacytoma of the breast: An unusual diagnosis. 61
32772461 2020
33
Solitary extramedullary plasmacytoma of the larynx: a rare cause of dysphonia. 61
32963040 2020
34
Persistent orofacial pain associated with nasopharyngeal extramedullary plasmacytoma. 61
33448451 2020
35
Extramedullary Plasmacytoma: Long-Term Clinical Outcomes in a Single-Center in China and Literature Review. 61
32941076 2020
36
Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK. 61
32934063 2020
37
Extramedullary plasmacytoma of hypopharynx treated using transoral laser microsurgery and adjuvant radiotherapy. 61
32773645 2020
38
A Rare Case of Extramedullary Plasmacytoma Presenting as Large Abdominal Mass. 61
32855895 2020
39
Multiple Upper Aerodigestive Tract Masses Presenting With Stridor-A Rare Case of Aggressive Multifocal Extramedullary Plasmacytoma. 61
32791898 2020
40
Jejunal extramedullary plasmacytoma. 61
32843223 2020
41
Primary extramedullary plasmacytoma of the eyelid conjunctiva - A case report and review of the literature. 61
32435472 2020
42
Extramedullary Plasmacytoma of the Stomach. 61
31042583 2020
43
Laparoscopic partial resection of retroperitoneal extramedullary plasmacytoma. 61
31610880 2020
44
Trabeculectomy in an unsuspected extramedullary iris-ciliary body plasmacytoma. 61
32314602 2020
45
First Reported Case of Extramedullary Plasmacytoma of the Appendix. 61
32362968 2020
46
Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry. 61
32321465 2020
47
Septal Nasal Extramedullary Plasmacytoma: A Rare Tumor in an Unusual Area. 61
32174154 2020
48
Extramedullary Plasmacytoma Involving the Heart: A Case Report and Focused Literature Review. 61
32337142 2020
49
Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis. 61
32183106 2020
50
Imaging features of extramedullary plasmacytoma. 61
31785037 2020

Variations for Extramedullary Plasmacytoma

Expression for Extramedullary Plasmacytoma

Search GEO for disease gene expression data for Extramedullary Plasmacytoma.

Pathways for Extramedullary Plasmacytoma

Pathways related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 IRF4 IL6 IL2RB IL2 IFI27 CDKN1A
2
Show member pathways
13.21 IRF4 IL6 IL2RB IL2 IFI27 CDKN1A
3
Show member pathways
13.14 IL6 IL2 CDKN1A CCND1 BCL2L1 BCL2
4
Show member pathways
12.89 IL6 IL2RB IL2 CDKN1A CCND1 BCL2L1
5
Show member pathways
12.87 IL6 CDKN1A CCND1 BCL2L1 BCL2 B2M
6
Show member pathways
12.71 IL6 IL2RB IL2 CDKN1A CCND1
7 12.7 IL6 IL2RB IL2 CDKN1A CCND1 BCL2L1
8
Show member pathways
12.68 IL6 IL2RB IL2 CDKN1A CCND1 BCL2L1
9
Show member pathways
12.53 IL6 IL2 CDKN1A BCL2L1 BCL2
10
Show member pathways
12.51 IRF4 IL6 IL2RB IL2 BCL2L1 BCL2
11 12.45 IRF4 IL2RB IL2 CD79A CD38 B2M
12
Show member pathways
12.43 IL6 CDKN1A CCND1 BCL2L1 BCL2
13
Show member pathways
12.34 IGKC CDKN1A CCND1 BCL2L1
14
Show member pathways
12.33 CDKN1A CCND1 BCL2L1 BCL2
15
Show member pathways
12.26 IL6 IL2RB IL2 CDKN1A CCND1 BCL2L1
16 12.21 IL6 IL2RB CDKN1A BCL2L1
17
Show member pathways
12.2 IRF4 IL6 IL2 IFI27
18
Show member pathways
12.19 CDKN1A CCND1 BCL2L1 BCL2
19
Show member pathways
12.17 IL2RB CDKN1A CCND1 BCL2L1 BCL2
20 12.14 IL6 CDKN1A CCND1 BCL2L1
21
Show member pathways
12.01 IL2RB IL2 BCL2
22 11.96 IL6 IL2 CCND1
23 11.93 CDKN1A CCND1 BCL2
24
Show member pathways
11.92 IL2RB IL2 B2M
25 11.9 IL6 CDKN1A BCL2
26 11.89 IL6 CDKN1A BCL2
27 11.86 IL6 CCND1 BCL2
28 11.85 CDKN1A CCND1 BCL2L1
29 11.84 IL6 IL2RB IL2 CDKN1A CCND1 BCL2L1
30 11.83 SDC1 IL6 CD79A
31 11.81 CDKN1A CCND1 BCL2L1 BCL2
32 11.8 SDC1 IL6 IL2RB IL2 CD79A CD38
33 11.77 IL6 IL2 CDKN1A
34 11.75 IRF4 IL2RB IL2
35 11.74 CDKN1A CCND1 BCL2
36 11.71 IRF4 IL6 IL2 CD38
37 11.7 CDKN1A BCL2L1 BCL2
38 11.69 IRF4 IL6 CDKN1A CCND1 BCL2L1 BCL2
39
Show member pathways
11.65 IL2RB IL2 BCL2L1 BCL2
40
Show member pathways
11.63 IL6 IL2 CCND1
41 11.61 CDKN1A CCND1 BCL2
42
Show member pathways
11.6 IL2RB IL2 B2M
43 11.55 IL6 CCND1 BCL2
44 11.49 IL6 CDKN1A CCND1 BCL2L1
45
Show member pathways
11.34 IL2RB IL2 BCL2
46 11.33 IL6 CCND1 BCL2L1
47 11.15 IL2 BCL2L1 BCL2
48 10.98 IL6 BCL2
49 10.81 IL6 IL2 CDKN1A CCND1 BCL2L1 BCL2
50 10.76 CDKN1A BCL2L1

GO Terms for Extramedullary Plasmacytoma

Cellular components related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 SDC1 IL2RB IGKC CD79A B2M

Biological processes related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 IL6 IL2 CD38 CCND1 BCL2L1 BCL2
2 negative regulation of apoptotic process GO:0043066 9.8 IL6 IL2RB IL2 CDKN1A CD38 BCL2L1
3 defense response to virus GO:0051607 9.78 IL6 IFI27 BCL2L1 BCL2
4 response to drug GO:0042493 9.77 CDKN1A CD38 CCND1 BCL2 B2M
5 response to toxic substance GO:0009636 9.72 SDC1 CDKN1A BCL2
6 response to organic substance GO:0010033 9.71 SDC1 CDKN1A CCND1
7 B cell receptor signaling pathway GO:0050853 9.71 IGKC CD79A CD38 BCL2
8 positive regulation of cell growth GO:0030307 9.69 IL2 CD38 BCL2
9 response to cytokine GO:0034097 9.63 CD38 BCL2L1 BCL2
10 response to X-ray GO:0010165 9.62 CDKN1A CCND1
11 positive regulation of immunoglobulin production GO:0002639 9.61 IL6 IL2
12 response to corticosterone GO:0051412 9.61 CDKN1A CCND1
13 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.61 IL2 BCL2L1 BCL2
14 negative regulation of anoikis GO:2000811 9.6 BCL2L1 BCL2
15 positive regulation of interleukin-17 production GO:0032740 9.59 IL6 IL2
16 response to iron ion GO:0010039 9.58 CCND1 BCL2
17 negative regulation of bone resorption GO:0045779 9.58 IL6 CD38
18 apoptotic mitochondrial changes GO:0008637 9.57 BCL2L1 BCL2
19 interleukin-2-mediated signaling pathway GO:0038110 9.56 IL2RB IL2
20 regulation of mitochondrial membrane permeability GO:0046902 9.52 BCL2L1 BCL2
21 T-helper 17 cell lineage commitment GO:0072540 9.49 IRF4 IL6
22 positive regulation of B cell proliferation GO:0030890 9.46 IL2 CDKN1A CD38 BCL2
23 response to glucocorticoid GO:0051384 9.35 SDC1 IL6 CDKN1A CCND1 BCL2
24 cytokine-mediated signaling pathway GO:0019221 9.28 SDC1 IRF4 IL6 IL2RB IL2 CDKN1A

Molecular functions related to Extramedullary Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 SDC1 IFI27 CD79A CD38 BCL2L1 BCL2
2 BH3 domain binding GO:0051434 8.62 BCL2L1 BCL2

Sources for Extramedullary Plasmacytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....